X4 Pharmaceuticals (XFOR) Assets Average (2018 - 2026)

X4 Pharmaceuticals (XFOR) has reported Assets Average for 9 consecutive years, with $261.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 122.53% year-over-year to $261.7 million; the trailing twelve-month figure through Jun 2026 stood at $261.7 million (up 122.53% YoY), and the FY2025 full-year result was $218.5 million, up 48.76% from the prior year.
• Assets Average slipped to $261.7 million in Q2 2026 per XFOR's latest filing, from $280.4 million in the prior quarter.
• Across five years, Assets Average topped out at $280.4 million in Q1 2026 and bottomed at $90.3 million in Q2 2022.
• Historically, Assets Average has averaged $158.9 million across 5 years, with a median of $144.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Assets Average slumped 40.32% in 2022, then surged 122.53% in 2026.
• Over 5 years, Assets Average stood at $134.5 million in 2022, then gained by 19.17% to $160.3 million in 2023, then advanced by 1.27% to $162.3 million in 2024, then surged by 39.86% to $227.0 million in 2025, then increased by 15.27% to $261.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $261.7 million, $280.4 million, and $227.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.